Special to the CJ
Mar 13, 2021
Ashley Loudermilk has become a strong advocate of colonoscopies after winning her battle with colorectal cancer. LCRH
When Ashley Loudermilk, a 37-year-old mother of three from Somerset, started experiencing extreme fatigue in early 2019, she was not overly concerned. She considered herself a hard-working, active adult who stayed busy with work, social activities and her kids. Her responsibilities and hobbies kept her busy, so feeling tired was not necessarily out of the norm. However, when more sleep and other interventions were not helping her situation, she started to wonder what else could be going on.
A few weeks later, Ashley noticed blood in her stool. It only happened a few times and she didnât associate it with any of her other symptoms. She simply wrote it off as hemorrhoids and assumed it would take care of itself.
So it s only fitting that Iron Range steelworkers have come to his aid.
Pfeiffer, eight, of Bovey, has undergone five rounds of chemotherapy, two surgeries, two stem cell transplants, 10 rounds of radiation, and six rounds of immunotherapy.
âWe could not ask for a tougher kid,â Easton s mother, Samantha Pfeiffer, a registered nurse at Grand Itasca Clinic & Hospital in Grand Rapids said. âBut when he s home, he s like a normal Easton. He s energetic, outgoing and likes to be outside riding his bike, fishing and camping.â
Easton s father Derek is a production truck driver at Hibbing Taconite Co.
Each day last week, United Steelworkers Local 2705 volunteers took donations at a Hibbing Taconite Co. gate to benefit Easton and his family.
Takeda Pharmaceutical Company Limited
Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next Decade1
Friday, March 12, 2021 11:40AM IST (6:10AM GMT)
Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030
Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets
Commitment to Patient Access to Medicines and Addressing Unmet Patient Needs in Emerging Markets Underpin Sustainable Growth
(TSE:4502/NYSE:TAK) (“Takeda”) today outlined its ambition for above-market, double-digit revenue growth of its Growth and Emerging Markets Business Unit (“GEM BU”). The revenue goal of JPY 1 trillion (approximately US$9 billion) by FY2030 represents more than doubling of current revenues in GEM BU. This potential growth will be primarily driven by a balanced geographical focus and targeted portfolio investments
Date Time
New targeted agent achieves impressive response rate in trial with patients with uterine serous carcinoma
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute reported.
The results of a phase 2 study published today in the Journal of Clinical Oncology showed that a WEE1-directed therapy in uterine serous carcinoma (USC), which accounts for about 10% of uterine cancers but up to 40% of deaths from the disease, demonstrated strong and durable activity.